BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

As companies and academic groups continue to form new partnerships and identify new drug targets to combat COVID-19, a National Academy of Sciences committee has warned there’s no guarantee the pandemic will be completely contained...
BioCentury | Jul 12, 2019
Preclinical News

July 12 Preclinical Quick Takes: Feng Zhang develops latest RNA editing platform, plus tools from David Liu and NIH

Zhang's RESCUE platform converts RNA C to U bases Feng Zhang and colleagues at Massachusetts Institute of Technology and the Broad Institute of MIT and Harvard have developed a single base RNA editing system that...
BioCentury | Apr 26, 2019
Financial News

Deerfield funding development of UIC discoveries with up to $65M

The University of Illinois at Chicago and Deerfield Management partnered to launch West Loop Innovations LLC (Chicago, Ill.) to house the university’s therapeutic discoveries. Deerfield will provide up to $65 million in research funding to...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Patient sample, cell culture, mouse and rat studies suggest inhibiting ENO1 could help treat pulmonary arterial hypertension (PAH) associated with other conditions. In pulmonary artery smooth muscle cell samples from patients with PAH...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection; sepsis Cell culture and mouse studies identified an odilorhabdin-based bacterial ribosomal 30S subunit inhibitor that could help treat bacterial sepsis and other bacterial infections. Screening of small molecules derived from 80 strains...
BioCentury | Apr 9, 2018
Preclinical News

Nosopharm team identifies new class of antibiotics

Researchers at Nosopharm S.A.S. (Nimes, France) and academic colleagues identified a previously unknown class of naturally produced antibiotics that binds to a new site within the bacterial ribosome's decoding center and induces miscoding, killing the...
BioCentury | Aug 3, 2017
Emerging Company Profile

Tunable cell therapies

Sigilon Therapeutics Inc. is developing allogeneic cell therapy implants for protein deficiency disorders that thread the needle between protein replacement therapies that require frequent dosing, and gene and cell therapies that are hard to dose-adjust....
BioCentury | Jun 2, 2017
Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
BioCentury | Feb 2, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies identified benzothiophene-based selective estrogen receptor down-regulators (SERDs) that could help treat drug-resistant breast cancers. Chemical synthesis and testing in cell-based assays of 6-OH-benzothiophene analogs identified six compounds...
BioCentury | Dec 13, 2016
Distillery Therapeutics

Cancer

INDICATION: Cancer In vitro and cell culture studies identified a HRAS - and KRAS -binding monobody that could help treat cancers driven by HRAS, KRAS or HER2 oncogenes. Screening of a combinatorial monobody library for HRAS...
Items per page:
1 - 10 of 56
BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

As companies and academic groups continue to form new partnerships and identify new drug targets to combat COVID-19, a National Academy of Sciences committee has warned there’s no guarantee the pandemic will be completely contained...
BioCentury | Jul 12, 2019
Preclinical News

July 12 Preclinical Quick Takes: Feng Zhang develops latest RNA editing platform, plus tools from David Liu and NIH

Zhang's RESCUE platform converts RNA C to U bases Feng Zhang and colleagues at Massachusetts Institute of Technology and the Broad Institute of MIT and Harvard have developed a single base RNA editing system that...
BioCentury | Apr 26, 2019
Financial News

Deerfield funding development of UIC discoveries with up to $65M

The University of Illinois at Chicago and Deerfield Management partnered to launch West Loop Innovations LLC (Chicago, Ill.) to house the university’s therapeutic discoveries. Deerfield will provide up to $65 million in research funding to...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Patient sample, cell culture, mouse and rat studies suggest inhibiting ENO1 could help treat pulmonary arterial hypertension (PAH) associated with other conditions. In pulmonary artery smooth muscle cell samples from patients with PAH...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection; sepsis Cell culture and mouse studies identified an odilorhabdin-based bacterial ribosomal 30S subunit inhibitor that could help treat bacterial sepsis and other bacterial infections. Screening of small molecules derived from 80 strains...
BioCentury | Apr 9, 2018
Preclinical News

Nosopharm team identifies new class of antibiotics

Researchers at Nosopharm S.A.S. (Nimes, France) and academic colleagues identified a previously unknown class of naturally produced antibiotics that binds to a new site within the bacterial ribosome's decoding center and induces miscoding, killing the...
BioCentury | Aug 3, 2017
Emerging Company Profile

Tunable cell therapies

Sigilon Therapeutics Inc. is developing allogeneic cell therapy implants for protein deficiency disorders that thread the needle between protein replacement therapies that require frequent dosing, and gene and cell therapies that are hard to dose-adjust....
BioCentury | Jun 2, 2017
Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
BioCentury | Feb 2, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies identified benzothiophene-based selective estrogen receptor down-regulators (SERDs) that could help treat drug-resistant breast cancers. Chemical synthesis and testing in cell-based assays of 6-OH-benzothiophene analogs identified six compounds...
BioCentury | Dec 13, 2016
Distillery Therapeutics

Cancer

INDICATION: Cancer In vitro and cell culture studies identified a HRAS - and KRAS -binding monobody that could help treat cancers driven by HRAS, KRAS or HER2 oncogenes. Screening of a combinatorial monobody library for HRAS...
Items per page:
1 - 10 of 56